Abstract
Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.
Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists
Current Signal Transduction Therapy
Title: Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Volume: 3 Issue: 3
Author(s): Simone Fulda
Affiliation:
Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists
Abstract: Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.
Export Options
About this article
Cite this article as:
Fulda Simone, Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs), Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699686
DOI https://dx.doi.org/10.2174/157436208785699686 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
Current Medicinal Chemistry Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells
Current Radiopharmaceuticals Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Design and Development of Glutathione Conjugated Poly (d, l) lactide Nanocarriers for Delivery of Hydrophilic Fluorescent Marker across Blood Brain Barrier
Current Nanoscience Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Nanoparticle-based Cerebral Drug-Delivery Systems and Antiangiogenic Approach in Gliomas Treatment
Recent Patents on Nanotechnology A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging
Current Protein & Peptide Science Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry